List of Excipients in Branded Drug DOLOPHINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
West-Ward Pharmaceuticals Corp	DOLOPHINE	methadone hydrochloride	0054-4218	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	DOLOPHINE	methadone hydrochloride	0054-4218	MAGNESIUM STEARATE
West-Ward Pharmaceuticals Corp	DOLOPHINE	methadone hydrochloride	0054-4218	STARCH, CORN

Dolophine Excipient Strategy and Commercial Opportunities for Methadone Hydrochloride

Last updated: October 21, 2026

Dolophine is a branded methadone hydrochloride product with limited composition-of-matter protection and low conventional patent barriers. Commercial value lies in excipient-enabled differentiation: dose accuracy, taste masking, stability, preservative selection, abuse-deterrent design, and formulations adapted for opioid treatment programs, hospitals, and chronic-pain patients. The most attractive opportunities are regulatory-compliant generic or 505(b)(2) products that improve handling and administration without changing methadone exposure.

What is Dolophine and which formulations does it cover?

Dolophine is a brand name for methadone hydrochloride, a synthetic opioid approved for analgesia and for management of opioid use disorder within federally regulated treatment settings. Methadone is available in oral tablets, oral solutions or concentrates, and injectable products. The commercial and regulatory profile differs materially by dosage form.

Product category	Typical strength or presentation	Primary commercial use	Excipient opportunity
Tablets	5 mg and 10 mg strengths	Pain management; opioid treatment programs	Disintegration, dose uniformity, swallowability, packaging
Oral concentrate or solution	Commonly 10 mg/mL presentations	Opioid treatment programs; controlled dosing	Taste masking, viscosity, preservative system, measuring accuracy
Injectable methadone	Parenteral presentations	Hospital and specialty use	Sterility, container compatibility, preservative-free design
Compounded or institutional liquid	Variable	Hospitals and treatment programs	Stability, unit-dose packaging, reduced preparation burden

The exact inactive ingredients depend on the manufacturer and dosage form. Methadone hydrochloride products commonly use conventional tablet excipients such as lactose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, and talc. Liquid products may use water, sweeteners, flavoring agents, pH modifiers, viscosity agents, and preservatives. Product-specific labeling must control any final formulation assessment. [1]

What patents protect Dolophine and methadone hydrochloride?

Methadone hydrochloride is an old active pharmaceutical ingredient. Its core composition-of-matter protection has expired, and generic methadone products have been marketed for decades. The primary competitive barriers are regulatory controls, controlled-substance compliance, manufacturing qualification, distribution restrictions, and clinical or institutional purchasing requirements.

Protection category	Strategic position
Methadone composition of matter	Expired
Basic oral tablet formulation	Generally vulnerable to generic competition
Basic oral solution	Generally vulnerable to generic competition
Method of treating pain	Broad historical claims are weak against modern generic entry
Opioid-treatment method claims	Limited commercial leverage unless tied to a specific formulation or delivery system
Abuse-deterrent formulation	Potentially protectable through composition, process, and use claims
Taste-masked liquid	Potentially protectable if the excipient combination produces a defined technical effect
Unit-dose or metering system	Potentially protectable through device or combination-product claims
Manufacturing process	Potentially protectable if it solves crystallization, impurity, content-uniformity, or stability problems

A new Dolophine-related patent would need to claim a real technical distinction. Broad claims covering methadone with routine pharmaceutical excipients would face enablement, written-description, obviousness, and anticipation challenges. Stronger candidates include narrow excipient ratios, pH-controlled systems, alcohol-free concentrates, low-temperature manufacturing processes, tamper-resistant packaging, and formulations that demonstrate improved stability or dose recovery.

When does Dolophine lose exclusivity?

Dolophine has no meaningful remaining exclusivity based on the age of methadone hydrochloride. The commercial question is therefore not whether a basic generic can enter, but whether a new product can obtain regulatory approval and capture a defensible niche.

FDA regulatory status and generic entry

Methadone hydrochloride products may use different FDA pathways depending on the proposed product:

• An ANDA under section 505(j) is the normal route for a pharmaceutically equivalent and bioequivalent generic.
• A 505(b)(2) application may be appropriate for a materially different formulation, route, strength, excipient system, dosing device, or clinical use.
• A new drug application may be required for a product with a new clinical claim or substantial formulation distinction.
• Products intended for opioid treatment programs must satisfy controlled-substance and program-specific requirements in addition to ordinary drug approval requirements.

Methadone is a Schedule II controlled substance. Manufacturing, storage, records, quotas, security, distribution, and diversion controls increase operating costs relative to ordinary oral solid generics. [2]

Orange Book status

The Orange Book is the relevant source for current listed products, patents, exclusivity, therapeutic equivalence codes, and reference-listed-drug status. Because methadone products have multiple dosage forms and manufacturers, Orange Book conclusions should be made at the NDA, strength, and dosage-form level rather than inferred from the Dolophine brand name alone. A current Orange Book review is required before relying on a particular patent listing or reference product. [3]

What excipient strategy is most commercially attractive for Dolophine?

The strongest strategy is to select excipients against a defined commercial problem. Excipient novelty alone has limited value. The formulation should generate a measurable advantage in stability, administration, safety, manufacturing yield, or treatment-program workflow.

1. Taste masking for oral methadone liquids

Methadone has a strong and persistent taste profile. Taste masking is commercially relevant because oral liquids are widely used in opioid treatment programs and among patients who cannot swallow tablets.

Potential technologies include:

• Ion-exchange resin complexes
• Cyclodextrin inclusion complexes
• Polymer coating of drug particles
• Lipid-based taste barriers
• Flavor systems combined with pH adjustment
• High-viscosity suspensions that reduce immediate taste perception
• Unit-dose cups or oral syringes that limit contact with the tongue

The formulation must preserve rapid and predictable methadone release. Excessive complexation or polymer coating can delay absorption and create bioequivalence risk. A successful product would need comparative dissolution, assay recovery, impurity, stability, and pharmacokinetic data.

Taste masking may support a 505(b)(2) product if the formulation differs materially from an approved reference product. A generic product using the same dosage form and therapeutic purpose would more likely require an ANDA and demonstrate bioequivalence.

2. Alcohol-free and low-excipient concentrates

Some methadone liquid formulations use solvents, sweeteners, preservatives, or flavoring systems that may be undesirable for pediatric, geriatric, institutional, or medically complex patients. An alcohol-free concentrate could target opioid treatment programs, hospitals, and specialty pharmacies.

Commercial advantages may include:

• Simplified handling
• Reduced solvent exposure
• Better compatibility with institutional policies
• More predictable dosing in patients with hepatic or metabolic concerns
• Lower flammability and storage burden
• Improved suitability for unit-dose packaging

The principal development issue is microbial control. Removing alcohol or reducing preservative concentration requires a validated preservative system, antimicrobial effectiveness testing, container-closure qualification, and in-use stability data.

3. Dose-accurate oral liquids

Methadone dosing errors can have serious clinical consequences because of its long and variable half-life, delayed respiratory depression, and nonlinear relationship between dose and clinical effect. A formulation that improves dosing accuracy can create value even when the active ingredient is generic.

Possible approaches include:

• Metered oral syringes
• Unit-dose cups
• Bottle adapters
• Integrated oral dosing pumps
• High-contrast graduations
• Concentration standardization
• Packaging that prevents accidental selection of the wrong strength

A device-linked product could support combination-product claims or device patents. The commercial advantage is strongest in opioid treatment programs, where large numbers of doses are prepared and administered under controlled procedures.

4. Tablet excipients for rapid, reproducible disintegration

Methadone tablets are mature products, so routine changes to fillers, binders, lubricants, or disintegrants are unlikely to create substantial market protection. Still, excipient selection can improve:

• Content uniformity at low dose
• Tablet robustness
• Disintegration across different gastric conditions
• Swallowability
• Compression speed
• Resistance to friability
• Stability under high humidity

A technically meaningful formulation may use a narrow combination of microcrystalline cellulose, co-processed excipients, superdisintegrants, and low-level lubricant. Patentability would depend on unexpected performance, not the presence of familiar excipients.

5. Abuse-deterrent formulation

An abuse-deterrent methadone product could use physical or chemical barriers against crushing, dissolution, extraction, or injection. Technologies may include:

• High-viscosity matrices
• Sequestration of methadone with an antagonist
• Crush-resistant tablets
• Gel-forming polymers
• Difficult-to-extract solid dispersions
• Tamper-evident unit-dose packaging

This opportunity has major technical and regulatory constraints. Methadone itself is a potent opioid, and any abuse-deterrent design must not create dose dumping, delayed toxicity, accidental exposure, or unpredictable absorption. FDA abuse-deterrence labeling requires evidence under the agency’s applicable guidance and does not establish that a product prevents abuse in all circumstances. [4]

What formulations are protected by methadone excipient patents?

Potentially protectable formulations fall into five categories.

Formulation concept	Patentable subject matter	Main weakness
Taste-masked liquid	Excipient combination, ratio, pH, particle coating, release profile	Routine flavor and sweetener combinations are vulnerable
Preservative-free liquid	Container, aseptic process, pH, antimicrobial control	Sterility and in-use stability burden
Abuse-deterrent tablet	Matrix, antagonist sequestration, crush resistance	High development cost and difficult clinical validation
Metered liquid system	Drug-device combination and dose-delivery geometry	Device patents may not block competing formulations
Stable high-concentration solution	Solvent system, pH, crystallization control	Must prove chemical and physical stability

The most defensible claims combine composition and performance. For example, a claim directed only to "methadone, a sweetener, and a flavor" is weak. A claim tied to a defined methadone concentration, pH range, viscosity, preservative concentration, taste threshold, stability period, and dissolution profile is stronger if supported by comparative data.

Which companies are challenging Dolophine?

Competition is fragmented among generic manufacturers, specialty pharmaceutical companies, hospital suppliers, and opioid-treatment suppliers. Methadone products have historically been marketed by companies including Hikma Pharmaceuticals through its West-Ward business, Roxane Laboratories, Mallinckrodt, and other generic manufacturers, depending on dosage form and market period.

The competitive field should be evaluated by:

1. FDA-approved strengths and dosage forms.
2. Therapeutic-equivalence ratings.
3. Current supply reliability.
4. Controlled-substance manufacturing capacity.
5. Treatment-program distribution networks.
6. Contract manufacturing capability.
7. Ability to support national DEA and state-level compliance.

A new entrant can compete without a novel active ingredient if it offers superior supply continuity, unit-dose packaging, lower preparation labor, or a formulation that reduces waste and dosing errors.

How strong is the patent estate for Dolophine?

The underlying Dolophine patent estate is weak by modern specialty-pharmaceutical standards because methadone is an old active ingredient and conventional dosage forms are established. A new formulation estate could become moderately strong if it includes multiple claim layers:

• Composition claims covering the excipient system.
• Process claims covering manufacturing and particle treatment.
• Use claims covering administration in a defined patient population.
• Device claims covering metered dosing.
• Packaging claims covering unit-dose or diversion-resistant systems.
• Stability claims covering a defined shelf life and storage condition.

Patent strength would depend on experimental support. The strongest evidence would compare the proposed formulation with existing methadone tablets or liquids and demonstrate improved taste, reduced dosing variability, lower degradation, better abuse-deterrence performance, or lower administration cost.

What patent litigation and Paragraph IV risks affect methadone products?

Basic methadone products face limited patent litigation risk because the active ingredient and conventional dosage forms are old. The more relevant litigation risks arise when a company develops a new formulation or delivery device.

Paragraph IV challenges

A Paragraph IV certification can arise if an ANDA applicant contends that a listed patent is invalid, unenforceable, or not infringed. For a new methadone formulation with Orange Book-listed patents, possible challengers would focus on:

• Routine optimization of known excipients
• Lack of unexpected results
• Anticipation by prior methadone liquids or tablets
• Obviousness based on taste-masking or controlled-release references
• Failure to claim a clinically meaningful difference
• Noninfringement based on excipient concentration or process differences

The commercial effect of a Paragraph IV filing depends on the listed patent, certification timing, litigation outcome, and availability of an alternative route such as a 505(b)(2) application.

Settlement agreements

There is no broadly recognized, market-defining Dolophine settlement framework comparable to major patented blockbuster drugs. Any settlement involving a particular methadone formulation would require review of the relevant court docket, FDA patent listing, and FTC or FDA settlement disclosures. Generic entry timing cannot be inferred from the Dolophine name alone.

What generic launch scenarios exist for Dolophine?

Scenario 1: Conventional oral tablet

This is the lowest-risk and lowest-differentiation pathway. A manufacturer competes on price, supply reliability, wholesaler access, and treatment-program contracts. Margins are likely to be pressured by multiple suppliers.

Scenario 2: Improved oral solution

A company launches a methadone solution with improved taste, standardized concentration, alcohol-free excipients, or a better dosing device. This can support premium pricing if the product reduces preparation labor or improves adherence.

Scenario 3: Hospital-focused injectable product

A preservative-free or supply-secure injectable product can target hospital formularies. The principal barriers are sterile manufacturing, container-closure validation, controlled-substance compliance, and reliable supply.

Scenario 4: Abuse-deterrent formulation

This has the largest potential differentiation but also the highest development and regulatory burden. A sponsor would need robust human-factors, abuse-potential, extractability, crushing, dissolution, and clinical data.

Scenario 5: Institutional unit-dose platform

A unit-dose oral liquid or tablet system can target opioid treatment programs, correctional health systems, hospitals, and public-sector buyers. The value proposition is operational rather than purely pharmacological.

How does Dolophine compare with other opioid formulations?

Attribute	Dolophine or conventional methadone	Buprenorphine products	Extended-release naltrexone
Active ingredient	Methadone	Buprenorphine, often with naloxone	Naltrexone
Controlled substance status	Schedule II	Schedule III	Not an opioid
Excipient opportunity	Taste, dosing accuracy, abuse deterrence, stability	Sublingual delivery, implants, injectables, depot systems	Depot suspension and injection-site performance
Main commercial buyer	Treatment programs, hospitals, pain prescribers	Treatment programs, office-based providers	Treatment programs and specialty providers
Manufacturing barrier	Controlled-substance and formulation controls	Complex transmucosal or depot delivery	Injectable depot manufacturing
Patent landscape	Mature active ingredient; formulation-led	More active formulation patent activity	Formulation and delivery patents

Methadone has a lower active-ingredient patent barrier than newer opioid use disorder products. Its commercial disadvantage is the regulatory and operational burden associated with Schedule II handling. Its advantage is established clinical use, low active pharmaceutical ingredient cost, and the ability to formulate multiple oral dosage forms.

What licensing deals could support a Dolophine opportunity?

Licensing opportunities are more likely to involve technology than methadone itself. Relevant assets include:

• Taste-masking platforms
• Ion-exchange resin systems
• Abuse-deterrent matrices
• Oral dosing devices
• Unit-dose packaging
• Preservative systems
• Controlled-substance manufacturing capacity
• Hospital and opioid-treatment distribution networks

A practical transaction structure could combine an excipient or device license with a contract manufacturing agreement. Milestones would typically be tied to formulation selection, FDA filing, approval, commercial launch, and net sales. The licensor should preserve rights for non-methadone applications while granting field-limited rights for methadone hydrochloride.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are operational rather than basic patent barriers.

Manufacturing barriers

• DEA registration and controlled-substance quotas
• Secure raw-material and finished-product storage
• Reconciliation and diversion controls
• High-potency containment
• Liquid-dose uniformity
• Microbial control for aqueous products
• Sterile manufacturing for injectables
• Stability in high-concentration solutions
• Container-closure compatibility
• Reliable supply of pharmaceutical-grade methadone hydrochloride

Intellectual-property barriers

• Existing taste-masking patents
• Resin-complex and polymer-coating patents
• Metering-device patents
• Abuse-deterrent formulation patents
• Manufacturing-process patents
• Trade secrets involving flavor systems, particle engineering, and scale-up

A freedom-to-operate review should cover active patents in the United States, Europe, Canada, Australia, and major opioid-treatment markets. Patent risk is likely to be concentrated around formulation technologies rather than methadone itself.

What is the commercial revenue opportunity for a new Dolophine formulation?

Conventional methadone tablets are likely to be a price-competitive generic market. The more attractive revenue pools are differentiated products with a clear institutional or patient benefit.

Opportunity	Pricing potential	Development burden	Commercial outlook
Standard tablet	Low	Low to moderate	Volume-driven
Standard oral solution	Low to moderate	Moderate	Stable institutional demand
Taste-masked liquid	Moderate to high	Moderate to high	Attractive if adherence or workflow improves
Metered unit-dose liquid	Moderate to high	Moderate	Strong treatment-program fit
Preservative-free injectable	Moderate	High	Hospital and shortage-resilience opportunity
Abuse-deterrent tablet	High	Very high	Selective, evidence-dependent
Specialty 505(b)(2) product	Moderate to high	High	Depends on clinical and regulatory differentiation

Revenue exposure is concentrated in opioid treatment programs, hospitals, public-sector health systems, and specialty distributors. A sponsor should avoid relying solely on retail pharmacy volume. Institutional contracts can provide more durable demand, but they often require validated supply continuity, controlled-substance compliance, and pricing discipline.

Key Takeaways

• Dolophine and methadone hydrochloride have little remaining basic patent value.
• Conventional tablets are primarily a low-margin generic opportunity.
• Excipient-led differentiation is most credible in taste masking, dose accuracy, stability, alcohol-free liquids, and unit-dose delivery.
• Abuse-deterrent methadone is technically possible but carries the highest regulatory and development risk.
• A 505(b)(2) strategy may be appropriate for a materially different liquid, device, route, or abuse-deterrent formulation.
• The strongest patent estate would combine composition, process, device, packaging, and performance claims.
• Controlled-substance compliance, manufacturing security, sterile capability, and distribution access are the main barriers to entry.
• Commercial value is highest where the formulation lowers treatment-program labor, reduces dosing errors, improves adherence, or protects supply.

FAQs About Dolophine Excipient and Commercial Strategy

Can a new methadone liquid obtain patent protection based only on better taste?

Usually not. A sponsor would need a defined formulation and evidence that the excipient system produces an unexpected taste-masking, stability, dissolution, or pharmacokinetic result.

Is a methadone oral solution eligible for 505(b)(2) approval?

It may be, if the proposed formulation differs materially from the reference product and the sponsor relies partly on FDA findings for an approved methadone product. The pathway depends on the formulation, labeling, dosage form, and extent of new supporting data.

Are excipients in Dolophine confidential?

The inactive ingredients for approved products are generally disclosed in FDA labeling and regulatory records. Manufacturing parameters, flavor systems, supplier qualifications, and scale-up controls may remain confidential trade secrets.

Can a unit-dose methadone package receive separate patent protection?

Yes. A unit-dose package, metering system, or controlled-dispensing device may support device or combination-product claims if it has a novel structure and solves a defined dosing, diversion, or handling problem.

Does methadone have biosimilar competition?

No. Methadone hydrochloride is a small-molecule drug, so competing products are approved as generics or through other small-molecule pathways, not as biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). Methadone hydrochloride prescribing information. FDA Drugs@FDA and product labeling database.

2. U.S. Drug Enforcement Administration. (n.d.). Drug scheduling and controlled-substance requirements. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. Center for Drug Evaluation and Research.